Pharmacological treatment of epilepsy in elderly people, a literature review.
Descripción del Articulo
Elderly people are at a higher risk of developing epilepsy. With a progressive increase in life expectancy, this is the fastest growing group of epilepsy patients. Their treatment is complicated by the presence of physiological changes related to aging, comorbidities, concomitant cognitive problems,...
Autor: | |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2022 |
Institución: | Universidad Peruana Cayetano Heredia |
Repositorio: | Revistas - Universidad Peruana Cayetano Heredia |
Lenguaje: | español |
OAI Identifier: | oai:revistas.upch.edu.pe:article/4155 |
Enlace del recurso: | https://revistas.upch.edu.pe/index.php/RNP/article/view/4155 |
Nivel de acceso: | acceso abierto |
Materia: | Elderly people epilepsy epileptic seizure drug , treatment Adulto mayor epilepsia fármacos anticrisis antiepiléptica tratamiento |
id |
REVUPCH_b047517199c4df2aaf4fa3d262d6a825 |
---|---|
oai_identifier_str |
oai:revistas.upch.edu.pe:article/4155 |
network_acronym_str |
REVUPCH |
network_name_str |
Revistas - Universidad Peruana Cayetano Heredia |
repository_id_str |
|
dc.title.none.fl_str_mv |
Pharmacological treatment of epilepsy in elderly people, a literature review. Tratamiento farmacológico de la epilepsia en el adulto mayor, revisión de la literatura. |
title |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
spellingShingle |
Pharmacological treatment of epilepsy in elderly people, a literature review. Bombón-Albán, Paulina E. Elderly people epilepsy epileptic seizure drug , treatment Adulto mayor epilepsia fármacos anticrisis antiepiléptica tratamiento |
title_short |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
title_full |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
title_fullStr |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
title_full_unstemmed |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
title_sort |
Pharmacological treatment of epilepsy in elderly people, a literature review. |
dc.creator.none.fl_str_mv |
Bombón-Albán, Paulina E. |
author |
Bombón-Albán, Paulina E. |
author_facet |
Bombón-Albán, Paulina E. |
author_role |
author |
dc.subject.none.fl_str_mv |
Elderly people epilepsy epileptic seizure drug , treatment Adulto mayor epilepsia fármacos anticrisis antiepiléptica tratamiento |
topic |
Elderly people epilepsy epileptic seizure drug , treatment Adulto mayor epilepsia fármacos anticrisis antiepiléptica tratamiento |
description |
Elderly people are at a higher risk of developing epilepsy. With a progressive increase in life expectancy, this is the fastest growing group of epilepsy patients. Their treatment is complicated by the presence of physiological changes related to aging, comorbidities, concomitant cognitive problems, complex drug interactions, and difficulties in the adherence to medication regimes. Seizures can be controlled in elderly people patients with low doses of a single epileptic seizure drug. Tolerability is an important factor in drug selection, as elderly people patients tend to be very sensitive to side effects. Enzyme-inducing anti-seizure drugs should gradually be left out of the therapeutic arsenal in favor of new anti-seizure drugs that have shown similar efficacy and better tolerability. Levetiracetam and lamotrigine are the most recommended anti-seizure drugs for elderly people with epilepsy nowadays. Although it could be easily controlled, it is recommended that elderly people continue their treatment indefinitely, due to the recurrent seizures’ proclivity. More studies are needed to address the pathophysiological mechanisms of epilepsy in this age group, and greater inclusion of elderly people in clinical trials is needed, as is the development of comprehensive care models to provide optimal patient care. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-03-21 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
https://revistas.upch.edu.pe/index.php/RNP/article/view/4155 10.20453/rnp.v85i1.4155 |
url |
https://revistas.upch.edu.pe/index.php/RNP/article/view/4155 |
identifier_str_mv |
10.20453/rnp.v85i1.4155 |
dc.language.none.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://revistas.upch.edu.pe/index.php/RNP/article/view/4155/4699 https://revistas.upch.edu.pe/index.php/RNP/article/view/4155/4824 |
dc.rights.none.fl_str_mv |
Derechos de autor 2022 Fernando Ardito; Paulina E. Bombón-Albán info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Derechos de autor 2022 Fernando Ardito; Paulina E. Bombón-Albán |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/html |
dc.publisher.none.fl_str_mv |
Universidad Peruana Cayetano Heredia |
publisher.none.fl_str_mv |
Universidad Peruana Cayetano Heredia |
dc.source.none.fl_str_mv |
Revista de Neuro-Psiquiatria; Vol. 85 No. 1 (2022): January-March; 55-65 Revista de Neuro-Psiquiatría; Vol. 85 Núm. 1 (2022): Enero-Marzo; 55-65 Revista de Neuro-Psiquiatria; v. 85 n. 1 (2022): Enero-Marzo; 55-65 1609-7394 0034-8597 reponame:Revistas - Universidad Peruana Cayetano Heredia instname:Universidad Peruana Cayetano Heredia instacron:UPCH |
instname_str |
Universidad Peruana Cayetano Heredia |
instacron_str |
UPCH |
institution |
UPCH |
reponame_str |
Revistas - Universidad Peruana Cayetano Heredia |
collection |
Revistas - Universidad Peruana Cayetano Heredia |
repository.name.fl_str_mv |
|
repository.mail.fl_str_mv |
|
_version_ |
1846152849352818688 |
spelling |
Pharmacological treatment of epilepsy in elderly people, a literature review.Tratamiento farmacológico de la epilepsia en el adulto mayor, revisión de la literatura.Bombón-Albán, Paulina E.Elderly peopleepilepsyepileptic seizure drug, treatmentAdulto mayorepilepsiafármacos anticrisis antiepilépticatratamientoElderly people are at a higher risk of developing epilepsy. With a progressive increase in life expectancy, this is the fastest growing group of epilepsy patients. Their treatment is complicated by the presence of physiological changes related to aging, comorbidities, concomitant cognitive problems, complex drug interactions, and difficulties in the adherence to medication regimes. Seizures can be controlled in elderly people patients with low doses of a single epileptic seizure drug. Tolerability is an important factor in drug selection, as elderly people patients tend to be very sensitive to side effects. Enzyme-inducing anti-seizure drugs should gradually be left out of the therapeutic arsenal in favor of new anti-seizure drugs that have shown similar efficacy and better tolerability. Levetiracetam and lamotrigine are the most recommended anti-seizure drugs for elderly people with epilepsy nowadays. Although it could be easily controlled, it is recommended that elderly people continue their treatment indefinitely, due to the recurrent seizures’ proclivity. More studies are needed to address the pathophysiological mechanisms of epilepsy in this age group, and greater inclusion of elderly people in clinical trials is needed, as is the development of comprehensive care models to provide optimal patient care.Los adultos mayores tienen mayor riesgo de desarrollar epilepsia. Con un aumento progresivo de la expectativa de vida, este grupo muestra el más rápido incremento entre los pacientes con epilepsia. El tratamiento en sí se complica debido a los cambios fisiológicos relacionados con el envejecimiento, las comorbilidades, los problemas cognitivos concomitantes, las interacciones farmacológicas complejas y las dificultades en la adherencia a regímenes medicamentosos. Las crisis epilépticas se pueden controlar en la mayoría de los pacientes adultos mayores con dosis bajas de un solo fármaco anticrisis epiléptica de efecto específico. La tolerabilidad es un factor importante en la selección del fármaco, ya que los pacientes adultos mayores tienden a ser muy sensibles a los efectos secundarios. Los fármacos anticrisis epiléptica que operan como inductores enzimáticos debe valorarse su retiro del arsenal terapéutico en favor de nuevos agentes que han demostrado similar eficacia y mejor tolerabilidad. Lamotrigina y levetiracetam son los fármacos anticrisis epiléptica más recomendados actualmente para el manejo de este cuadro en los adultos mayores. Aun cuando puede tratarse de una epilepsia fácilmente controlable, es recomendable mantener el tratamiento de forma indefinida en los adultos mayores dada la tendencia recurrente de las crisis. Se requieren más estudios que aborden los mecanismos fisiopatológicos de la epilepsia en este grupo etario y una mayor inclusión de los adultos mayores en ensayos clínicos, así como el desarrollo de modelos de atención integral que optimice el cuidado de estos pacientes.Universidad Peruana Cayetano Heredia2022-03-21info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdftext/htmlhttps://revistas.upch.edu.pe/index.php/RNP/article/view/415510.20453/rnp.v85i1.4155Revista de Neuro-Psiquiatria; Vol. 85 No. 1 (2022): January-March; 55-65Revista de Neuro-Psiquiatría; Vol. 85 Núm. 1 (2022): Enero-Marzo; 55-65Revista de Neuro-Psiquiatria; v. 85 n. 1 (2022): Enero-Marzo; 55-651609-73940034-8597reponame:Revistas - Universidad Peruana Cayetano Herediainstname:Universidad Peruana Cayetano Herediainstacron:UPCHspahttps://revistas.upch.edu.pe/index.php/RNP/article/view/4155/4699https://revistas.upch.edu.pe/index.php/RNP/article/view/4155/4824Derechos de autor 2022 Fernando Ardito; Paulina E. Bombón-Albáninfo:eu-repo/semantics/openAccessoai:revistas.upch.edu.pe:article/41552023-08-08T17:11:05Z |
score |
12.783859 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).